Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies

Sho Moriguchi, Akihiro Takamiya, Yoshihiro Noda, Nobuyuki Horita, Masataka Wada, Sakiko Tsugawa, Eric Plitman, Yasunori Sano, Ryosuke Tarumi, Muhammad ElSalhy, Nariko Katayama, Kamiyu Ogyu, Takahiro Miyazaki, Taishiro Kishimoto, Ariel Graff-Guerrero, Jeffrey H. Meyer, Daniel M. Blumberger, Zafiris J. Daskalakis, Masaru Mimura, Shinichiro Nakajima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.

Original languageEnglish
JournalMolecular Psychiatry
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Major Depressive Disorder
Meta-Analysis
Depression
Frontal Lobe
Glutamic Acid
Glutamine
Synaptic Transmission
Magnetic Resonance Spectroscopy
Proton Magnetic Resonance Spectroscopy
MEDLINE
Protons
Spectrum Analysis

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Glutamatergic neurometabolite levels in major depressive disorder : a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. / Moriguchi, Sho; Takamiya, Akihiro; Noda, Yoshihiro; Horita, Nobuyuki; Wada, Masataka; Tsugawa, Sakiko; Plitman, Eric; Sano, Yasunori; Tarumi, Ryosuke; ElSalhy, Muhammad; Katayama, Nariko; Ogyu, Kamiyu; Miyazaki, Takahiro; Kishimoto, Taishiro; Graff-Guerrero, Ariel; Meyer, Jeffrey H.; Blumberger, Daniel M.; Daskalakis, Zafiris J.; Mimura, Masaru; Nakajima, Shinichiro.

In: Molecular Psychiatry, 01.01.2018.

Research output: Contribution to journalArticle

Moriguchi, S, Takamiya, A, Noda, Y, Horita, N, Wada, M, Tsugawa, S, Plitman, E, Sano, Y, Tarumi, R, ElSalhy, M, Katayama, N, Ogyu, K, Miyazaki, T, Kishimoto, T, Graff-Guerrero, A, Meyer, JH, Blumberger, DM, Daskalakis, ZJ, Mimura, M & Nakajima, S 2018, 'Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies', Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0252-9
Moriguchi, Sho ; Takamiya, Akihiro ; Noda, Yoshihiro ; Horita, Nobuyuki ; Wada, Masataka ; Tsugawa, Sakiko ; Plitman, Eric ; Sano, Yasunori ; Tarumi, Ryosuke ; ElSalhy, Muhammad ; Katayama, Nariko ; Ogyu, Kamiyu ; Miyazaki, Takahiro ; Kishimoto, Taishiro ; Graff-Guerrero, Ariel ; Meyer, Jeffrey H. ; Blumberger, Daniel M. ; Daskalakis, Zafiris J. ; Mimura, Masaru ; Nakajima, Shinichiro. / Glutamatergic neurometabolite levels in major depressive disorder : a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. In: Molecular Psychiatry. 2018.
@article{0288400e28834101a46ee04a9c595e69,
title = "Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies",
abstract = "Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95{\%} CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95{\%} CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95{\%} CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.",
author = "Sho Moriguchi and Akihiro Takamiya and Yoshihiro Noda and Nobuyuki Horita and Masataka Wada and Sakiko Tsugawa and Eric Plitman and Yasunori Sano and Ryosuke Tarumi and Muhammad ElSalhy and Nariko Katayama and Kamiyu Ogyu and Takahiro Miyazaki and Taishiro Kishimoto and Ariel Graff-Guerrero and Meyer, {Jeffrey H.} and Blumberger, {Daniel M.} and Daskalakis, {Zafiris J.} and Masaru Mimura and Shinichiro Nakajima",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41380-018-0252-9",
language = "English",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glutamatergic neurometabolite levels in major depressive disorder

T2 - a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies

AU - Moriguchi, Sho

AU - Takamiya, Akihiro

AU - Noda, Yoshihiro

AU - Horita, Nobuyuki

AU - Wada, Masataka

AU - Tsugawa, Sakiko

AU - Plitman, Eric

AU - Sano, Yasunori

AU - Tarumi, Ryosuke

AU - ElSalhy, Muhammad

AU - Katayama, Nariko

AU - Ogyu, Kamiyu

AU - Miyazaki, Takahiro

AU - Kishimoto, Taishiro

AU - Graff-Guerrero, Ariel

AU - Meyer, Jeffrey H.

AU - Blumberger, Daniel M.

AU - Daskalakis, Zafiris J.

AU - Mimura, Masaru

AU - Nakajima, Shinichiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.

AB - Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.

UR - http://www.scopus.com/inward/record.url?scp=85054730377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054730377&partnerID=8YFLogxK

U2 - 10.1038/s41380-018-0252-9

DO - 10.1038/s41380-018-0252-9

M3 - Article

C2 - 30315224

AN - SCOPUS:85054730377

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -